Blinatumoab公司
微小残留病
淋巴细胞白血病
完全缓解
医学
耐火材料（行星科学）
化疗
白血病
肿瘤科
内科学
生物
天体生物学
作者
Mark R. Litzow,Zhuoxin Sun,Ryan J. Mattison,Elisabeth Paietta,Kathryn G. Roberts,Yanming Zhang,Janis Racevskis,Hillard M. Lazarus,Jacob M. Rowe,Daniel A. Arber,Matthew J. Wieduwilt,Michaela Liedtke,Julie Bergeron,Brent L. Wood,Yaqi Zhao,Gang Wu,Ti‐Cheng Chang,Wenchao Zhang,Keith W. Pratz,Shira Dinner
标识
DOI：10.1056/nejmoa2312948
摘要
The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. (Funded by the National Institutes of Health and others; E1910 ClinicalTrials.gov number, NCT02003222.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
dde
无极微光
HFH
AllRightReserved
嘻嘻哈哈
Rainyin
张欢馨
科研狗
arniu2008
GingerF
蓝天
369ninja
lizishu
乐空思
eric888
OK
木子也是李
qwert118
尊嘟假嘟
皖公网安备34019202002308
